P&G Throws Weight Behind Consumer Growth After Shedding Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Since many of its key consumer product lines are already mature U.S. brands, Procter & Gamble will have to drive growth by expanding into new markets and acquiring either hard-to-find licenses for OTC switch candidates or existing nonprescription brands.
You may also be interested in...
Teva Stakes OTC Claim With P&G Joint Venture
Teva is making a big push into OTCs, announcing a joint venture with Procter & Gamble to combine OTC businesses outside North America.
Teva Stakes OTC Claim With P&G Joint Venture
Teva is making a big push into OTCs, announcing a joint venture with Procter & Gamble to combine OTC businesses outside North America.
Back In The Game: One Year After Rx Exit, P&G Signs On To Promote Silenor
Somaxon and P&G are preparing to launch the insomnia drug in September with a combined sales force of 215 reps.